 Study hypothesis: The initiation of NRTI-containing, PI-sparing therapy will inhibit mitochondrial DNA mtDNA synthesis and lead to a decrease in mtDNA content in adipose tissue, skeletal muscle and peripheral blood mononuclear cells PBMCs, will cause deterioration in mitochondrial function, will increase fat apoptosis and oxidative damage biomarkers, and will lead to progressive decrease in body fat content. 